Upgrade of revenue and operating profit guidance

What happened

ChemoMetec raised its 2026/27 revenue forecast to DKK 570–605 million from DKK 560–590 million, and its EBITDA forecast to DKK 335–360 million from DKK 330–345 million. It cited stronger-than-expected instrument demand, especially for the NC-203, and lower-than-expected costs. Q1 revenue rose 28% to DKK 160.0 million, while EBITDA was DKK 100.3 million.

Confirmed

Global impact / market context

Higher expected sales and a lower cost base could lift ChemoMetec’s earnings if demand and cost savings persist. This matters because the company sells instruments to pharmaceutical, biotech and agricultural customers, so sustained purchases can support revenue while cost control can increase the share of sales left as operating profit.

Analyst inference

The guidance increase follows reported Q1 revenue growth and an EBITDA margin of 63%, up from 55% a year earlier; EBITDA margin means EBITDA as a share of revenue. The announcement points to both stronger instrument demand and lower costs, rather than sales growth alone, supporting the higher forecast.

Confirmed

What to watch

1. The scheduled Q1 results release on 5 November 2026 may provide detail on instrument demand, including the NC-203, and whether the quarter’s growth continued. Confirmed
2. Compare reported 2026/27 revenue and EBITDA with the new ranges of DKK 570–605 million and DKK 335–360 million to assess delivery against guidance. Analyst inference
3. Check whether the company says lower costs are recurring or temporary, since that distinction affects how much of the higher EBITDA forecast may carry into future periods. Analyst inference

Evidence

• globenewswire.com